Intra-Cellular Therapies, Inc. (ITCI)
131.87
0.00 (0.00%)
Inactive · Last trade price on Apr 1, 2025
Intra-Cellular Therapies Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 306.95 | 147.77 | 148.62 | 92.37 | 60.05 |
Short-Term Investments | 694.12 | 350.17 | 443.29 | 319.97 | 597.4 |
Cash & Short-Term Investments | 1,001 | 497.94 | 591.91 | 412.33 | 657.45 |
Cash Growth | 101.04% | -15.88% | 43.55% | -37.28% | 193.49% |
Accounts Receivable | 166.5 | 114.02 | 75.19 | 20.16 | 10.76 |
Other Receivables | 5 | 2.3 | - | - | - |
Receivables | 171.5 | 116.32 | 75.19 | 20.16 | 10.76 |
Inventory | 26.28 | 11.65 | 23.92 | 7.95 | 7.06 |
Prepaid Expenses | 68.47 | 32.24 | 23.59 | 15.94 | 14.24 |
Restricted Cash | 1.75 | 1.75 | 1.75 | 1.4 | 1.4 |
Other Current Assets | 38.3 | 7.9 | 21.6 | 9.5 | - |
Total Current Assets | 1,307 | 667.8 | 737.96 | 467.28 | 690.9 |
Property, Plant & Equipment | 14.9 | 14.58 | 16.74 | 22.56 | 26.32 |
Other Long-Term Assets | 44.65 | 45.91 | 0.09 | 0.09 | 0.09 |
Total Assets | 1,367 | 728.3 | 754.78 | 489.92 | 717.31 |
Accounts Payable | 26.07 | 11.45 | 10.4 | 8.69 | 5.5 |
Accrued Expenses | 175.4 | 108.48 | 68.27 | 37.93 | 25.81 |
Current Portion of Leases | 4.23 | 3.61 | 4.57 | 6.73 | 5.54 |
Total Current Liabilities | 205.7 | 123.55 | 83.24 | 53.36 | 36.85 |
Long-Term Leases | 12.75 | 13.33 | 15.47 | 18.68 | 23.6 |
Total Liabilities | 218.45 | 136.87 | 98.71 | 72.03 | 60.45 |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Additional Paid-In Capital | 2,840 | 2,208 | 2,138 | 1,639 | 1,593 |
Retained Earnings | -1,692 | -1,617 | -1,477 | -1,221 | -937.1 |
Comprehensive Income & Other | 0.19 | 0.1 | -4.19 | -0.36 | 0.48 |
Shareholders' Equity | 1,148 | 591.42 | 656.07 | 417.89 | 656.86 |
Total Liabilities & Equity | 1,367 | 728.3 | 754.78 | 489.92 | 717.31 |
Total Debt | 16.98 | 16.94 | 20.04 | 25.41 | 29.14 |
Net Cash (Debt) | 984.09 | 481 | 571.86 | 386.93 | 628.31 |
Net Cash Growth | 104.59% | -15.89% | 47.80% | -38.42% | 212.80% |
Net Cash Per Share | 9.54 | 5.02 | 6.08 | 4.76 | 8.93 |
Filing Date Shares Outstanding | 106.33 | 96.81 | 95.28 | 93.59 | 80.92 |
Total Common Shares Outstanding | 106.24 | 96.38 | 94.83 | 81.89 | 80.46 |
Working Capital | 1,102 | 544.25 | 654.72 | 413.92 | 654.05 |
Book Value Per Share | 10.81 | 6.14 | 6.92 | 5.10 | 8.16 |
Tangible Book Value | 1,148 | 591.42 | 656.07 | 417.89 | 656.86 |
Tangible Book Value Per Share | 10.81 | 6.14 | 6.92 | 5.10 | 8.16 |
Machinery | - | - | - | 5.12 | 4.79 |
Leasehold Improvements | - | - | - | 1.24 | 1.24 |